BioNTech Results Presentation Deck
Strong Position and Outlook for Global COVID-19 Vaccine Franchise
28
>3.6 bn doses shipped to 180 countries or territories since product launch¹
Increasing market share since January 2022²
All markets 3³: increase from 52% to 63%
Developed markets 4: increase from 59% to 68%
●
2022 order book: -2.5 bn doses
●
U.S. government ordered additional 105 m doses with value of $3.2 bn
Option for another 195 m doses
• EC order of 650 m doses for delivery in 2022
• Amended contract for rephasing deliveries toward Q4 2022
●
●
Shipment volumes expected to increase with planned launch of
Omicron variant-adapted vaccines in the late fall5
1 As of beginning of July 2022
2 Cumulative Share of Doses from January 1, 2022 to July 20, 2022 in markets in which Pfizer and BioNTech operate and that report market share data
3 Incl. all markets in Developed Markets (4) plus Emerging Markets (Argentina, Chile, Ecuador, Hong Kong, Nepal, Peru, South Africa, Uruguay)
4 Includes the U.S., EU/EEA, other Int'l Developed markets (Japan, South Korea, Switzerland, Ukraine)
5 Starting date of January 1, 2022 for this data set is from Q1 2022 earnings presentation
5 Pending regulatory approval
Distribution of COVID-10 vaccine in collaboration with Pfizer
BIONTECHView entire presentation